Wake Forest NeuroNext Clinical Site (WAKENN)

维克森林浸信会健康（WFBH）致力于提供神经病学临床试验，我们的历史上代表性不足，地理位置不同的患者在我们的6家医院的卫生系统和我们的26个县集水区。加入NeuroNEXT网络作为一个临床站点将把目前未发现的东南大西洋纳入国家网络，并通过我们多样化的患者组合来增强它。我们四分之三的病人生活在农村社区，相当大一部分人生活在联邦贫困线以下。值得注意的是，北卡罗来纳州拥有密西西比河以东最多的美洲印第安人，也是全国增长最快的西班牙裔人口之一。此外，WFBH是美国为数不多的完全整合的学术卫生系统之一，我们带来了临床试验的经验，专注的领导力，以及在神经病学培训下一代临床科学家的成功记录。随着我们新的首席执行官/院长对机构资源的坚定承诺，WFBH拥有强大的研究基础设施，包括我们的CTSA资助的临床和转化科学研究所（CTSI），Maya Angelou健康公平中心，NIA资助的Pepper老年美国人独立和阿尔茨海默病核心中心，以及一个杰出的公共卫生科学部门，在多中心临床试验方面拥有丰富的经验，并与NIH协调中心合作。WFBH还致力于培养多样化的下一代神经科学研究人员。WFBH在过去5年中获得了12项神经科学K奖，神经病学是临床试验收入的机构领导者（WFBH获得的非NIH收入的17.5%）。凭借这些多重优势，我们将通过执行这些特定目标为NeuroNEXT网络做出有意义的贡献：目标1：利用我们地理上、种族上和经济上多样化的集水区，有效地招募和留住来自历史上服务不足人群的临床试验参与者。这包括北卡罗来纳州西部和弗吉尼亚州南部，农村阿巴拉契亚，以及大城市，西班牙裔和非洲裔美国人的人口。目标2：让我们的患者社区参与研究过程，利用我们目前的利益相关者外展基础设施来促进NeuroNEXT试验。目标3：利用我们的综合学术医疗中心的资源来激励，协调和透明地跟踪临床试验的创建，增长和实施。目的4：招募和培训下一代神经学研究人员，以设计和实施有意义的和可重复的临床试验。Brashear和邓肯博士以及整个WFBH研究领导层都热衷于为NeuroNEXT网络提供我们独特的患者组合，强大的研究团队，强大的神经病学临床试验研究环境，高效的监管和合同执行团队，以及对神经疾病有前途的疗法进行高效和可重复试验的专业知识。

Wake Forest Baptist Health (WFBH) is committed to providing neurology clinical trials to our historically underrepresented and geographically diverse patients across our 6-hospital health system and our 26-county catchment area. Joining the NeuroNEXT network as a clinical site would bring the currently uncovered Southeast Atlantic into the national network and enhance it with our diverse patient mix. Three-quarters of our patients live in rural communities and a substantial proportion are below the federal poverty level. Of note, North Carolina has the largest population of American Indians east of the Mississippi River, and one of the fastest-growing Hispanic populations in the nation. Furthermore, WFBH is one of the few fully integrated academic health systems in the U.S. We bring experience in clinical trials, dedicated leadership, and a successful track record of training the next generation of clinician-scientists in neurology. With a strong commitment of institutional resources from our new CEO/Dean, WFBH has robust research infrastructure that includes our CTSA-funded Clinical and Translational Science Institute (CTSI), Maya Angelou Center for Health Equity, NIA-funded Pepper Older Americans Independence and Alzheimer’s Disease Core Centers, and an outstanding Division of Public Health Sciences with extensive experience with multi-site clinical trials and working with NIH coordinating centers. WFBH is also dedicated to training a diverse next generation of neuroscience investigators. WFBH has received 12 Neuroscience K awards in the last 5 years and Neurology is an institutional leader in clinical trial revenues (17.5% of non-NIH income received by WFBH). With these multiple strengths, we will contribute meaningfully to the NeuroNEXT network by carrying out these Specific Aims: AIM 1: To leverage our geographically, ethnically, and economically diverse catchment area to effectively enroll and retain clinical trial participants from historically underserved populations. This includes western North Carolina and southern Virginia, rural Appalachia, and large urban, Hispanic, and African American populations. AIM 2: To engage our patient community in the research process, leveraging our current stakeholder outreach infrastructure to promote NeuroNEXT trials. AIM 3: To leverage the resources of our integrated academic medical center to incentivize, coordinate, and transparently track clinical trial creation, growth, and implementation. AIM 4: To recruit and train the next generation of neurology researchers to design and implement meaningful and reproducible clinical trials. Our experienced co-PIs, Drs. Brashear and Duncan, together with the entire WFBH research leadership, are enthusiastic in offering to the NeuroNEXT network our unique patient mix, strong investigative group, robust research environment for neurology clinical trials, efficient regulatory and contract execution teams, and expertise in conducting efficient and reproducible trials of promising therapies for neurologic disorders.